Fig. 1: IGHV1-2 genotype, allele, and pre-vaccination IgM repertoire distributions for IAVI G001 trial participants.

a The IGHV1-2 allele content in each study participant was determined by sequencing bulk IgM libraries and inferring the IGHV allele content in each case with IgDiscover. Quantitative analyses of mRNA expression levels and HCDR3 frequencies followed. b Number of each genotype and c number of each allele, for all trial participants (n = 48). d Number of vaccine recipients per group, out of 18, with each allele (*02, *04, *05, and *06), with the *02 variant *02_S4953 classified as *02. P-values are based on a Fisher’s exact test with values >0.05 marked as not significant (NS). For all 48 participants, pre-vaccination e mRNA expression frequencies and f unique HCDR3 frequencies for each IGHV1-2 allele are shown as points color-coded by allele and grouped by homozygous and heterozygous genotype. Each point represents a trial participant, with heterozygous participants represented by two points. Thick lines are median values and boxes are the 25% and 75% quantiles. g Correlation between mRNA count and unique HCDR3 count; h Ratio of unique HCDR3 count to mRNA count versus mRNA count; i Correlation between frequency of mRNA expression and frequency of unique HCDR3s; and j Ratio of the unique HCDR3 frequency to the mRNA frequency versus the mRNA frequency, are shown for pre-vaccination repertoires. Points are shape- and color-coded by IGHV1-2 allele as shown in the legend of (g–j). Pearson correlation coefficients (r) for counts and frequencies are shown in (g and i), respectively. In panels h and j, the solid line is the median ratio, and the shaded region shows the inter-quartile range.